199 related articles for article (PubMed ID: 31911716)
1. We Can use Market Forces to Moderate Drug Prices.
Miller HI
Mo Med; 2019; 116(6):451-453. PubMed ID: 31911716
[No Abstract] [Full Text] [Related]
2. [Competition and prices in the Mexican pharmaceutical market].
Molina-Salazar RE; González-Marín E; Carbajal-de Nova C
Salud Publica Mex; 2008; 50 Suppl 4():S496-503. PubMed ID: 19082261
[TBL] [Abstract][Full Text] [Related]
3. Realizing two-tiered innovation policy through drug regulation.
Ridgway WE
Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
[No Abstract] [Full Text] [Related]
4. [Healthy pharmaceutical policy].
González Pier E
Salud Publica Mex; 2008; 50 Suppl 4():S488-95. PubMed ID: 19082260
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceuticals and medical devices: business practices. Issue brief.
Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448
[No Abstract] [Full Text] [Related]
6. The calculus of cures.
Kocher R; Roberts B
N Engl J Med; 2014 Apr; 370(16):1473-5. PubMed ID: 24571723
[No Abstract] [Full Text] [Related]
7. FDA chief attacks Canada's drug price controls.
Webster P
Lancet; 2003 Nov; 362(9398):1816. PubMed ID: 14661624
[No Abstract] [Full Text] [Related]
8. Top 100 bestselling drugs represent an arena struggling for new FDA approvals: drug age as an efficiency indicator.
Polanski J; Bogocz J; Tkocz A
Drug Discov Today; 2015 Nov; 20(11):1300-4. PubMed ID: 26160060
[TBL] [Abstract][Full Text] [Related]
9. The Myth of the Free Market for Pharmaceuticals.
Conti RM; Frank RG; Cutler DM
N Engl J Med; 2024 Apr; 390(16):1448-1450. PubMed ID: 38647106
[No Abstract] [Full Text] [Related]
10. Balancing government regulation against access to drugs: address to Seton Hall University School of Law, February 16, 2007.
Meron D
Seton Hall Law Rev; 2007; 37(4):929-39. PubMed ID: 18363219
[No Abstract] [Full Text] [Related]
11. Drug Regulation and Pricing--Can Regulators Influence Affordability?
Eichler HG; Hurts H; Broich K; Rasi G
N Engl J Med; 2016 May; 374(19):1807-9. PubMed ID: 27168431
[No Abstract] [Full Text] [Related]
12. Why are we Being Overcharged for Pharmaceuticals? What Should We Do About It?
Hyman DA; Silver C
J Leg Med; 2019; 39(2):137-149. PubMed ID: 31503533
[No Abstract] [Full Text] [Related]
13. The hidden cost of low prices: limited access to new drugs in India.
Berndt ER; Cockburn IM
Health Aff (Millwood); 2014 Sep; 33(9):1567-75. PubMed ID: 25201661
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceuticals and medical devices: business practices.
Steiner DJ
Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
[No Abstract] [Full Text] [Related]
15. The $2.6 billion pill--methodologic and policy considerations.
Avorn J
N Engl J Med; 2015 May; 372(20):1877-9. PubMed ID: 25970049
[No Abstract] [Full Text] [Related]
16. Market watch: Top drugs and companies by sales in 2017.
Urquhart L
Nat Rev Drug Discov; 2018 Mar; 17(4):232. PubMed ID: 29588516
[No Abstract] [Full Text] [Related]
17. The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States.
Gupta R; Dhruva SS; Fox ER; Ross JS
J Manag Care Spec Pharm; 2017 Oct; 23(10):1066-1076. PubMed ID: 28944731
[TBL] [Abstract][Full Text] [Related]
18. Costing drug development.
Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
[No Abstract] [Full Text] [Related]
19. Patients not patents: Drug research and development as a public enterprise.
Gøtzsche PC
Eur J Clin Invest; 2018 Feb; 48(2):. PubMed ID: 29243246
[No Abstract] [Full Text] [Related]
20. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
